Lafarge, Maxime WDomingo, EnricSirinukunwattana, KorsukWood, RubySamuel, LeslieMurray, GraemeRichman, Susan DBlake, AndrewSebag-Montefiore, DavidGollins, SimonKlieser, EckhardNeureiter, DanielHuemer, FlorianGreil, RichardDunne, PhilipQuirke, PhilipWeiss, LukasRittscher, JensMaughan, TimKoelzer, Viktor H2024-04-102024-04-102024-04-09Lafarge, M W, Domingo, E, Sirinukunwattana, K, Wood, R, Samuel, L, Murray, G, Richman, S D, Blake, A, Sebag-Montefiore, D, Gollins, S, Klieser, E, Neureiter, D, Huemer, F, Greil, R, Dunne, P, Quirke, P, Weiss, L, Rittscher, J, Maughan, T & Koelzer, V H 2024, 'Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy', NPJ precision oncology, vol. 8, no. 1, 89. https://doi.org/10.1038/s41698-024-00580-32397-768XORCID: /0000-0002-8402-8670/work/157656637https://hdl.handle.net/2164/23216Acknowledgements The authors thank Aurelien de Reynies for advice on CMS calling in FFPE blocks, Claire Butler and Michael Youdell for excellent managing in S:CORT and the MRC Clinical Trials Unit who provided the clinical data from the FOCUS trial with permission from the FOCUS trial steering group. The S:CORT consortium is a Medical Research Council stratified medicine consortium jointly funded by the MRC and CRUK (MR/M016587/1). The ARISTOTLE trial was funded by Cancer Research UK (CRUK/08/032). This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. This work was supported by the Research Fund of the Paracelsus Medical University Salzburg, Austria (PMU-FFF R-17/03/090-HUW). Computation used the CTP Lab core resources at the University of Zurich and the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. RW is supported through the EPSRC Center for Doctoral Training in Health Data Science (EP/S02428X/1), Oxford CRUK Cancer Centre. JR is supported through the NIHR Oxford Biomedical Research Centre, the Oxford CRUK Cancer Center, and holds an adjunct appointment at the Ludwig Institute of Cancer Research at the University of Oxford. TM gratefully acknowledges funding by the Medical Research Council and Cancer Research UK. VHK gratefully acknowledges funding by the Swiss National Science Foundation (P2SKP3_168322/1 and P2SKP3_168322/2), and the Promedica Foundation (F-87701-41-01). The results published or shown here are based in part upon data generated by the TCGA Research Network established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov. The funders played no role in the analyses performed or the results presented. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.112502079engSDG 3 - Good Health and Well-beingTraditional researchTumour biomarkersR MedicineMedical Research Council (MRC)MR/M016587/1Cancer Research UKCRUK/08/032Engineering and Physical Sciences Research Council (EPSRC)EP/S02428X/1Supplementary InformationRJournal article10.1038/s41698-024-00580-381